Literature DB >> 7812911

Expansion of the Ki-67 proliferative compartment correlates with degree of dysplasia in Barrett's esophagus.

M K Hong1, W B Laskin, B E Herman, M H Johnston, J J Vargo, S M Steinberg, C J Allegra, P G Johnston.   

Abstract

BACKGROUND: Barrett's esophagus is a histologically defined premalignant lesion of the esophagus in which normal squamous epithelium is replaced by intestinalized columnar epithelium. In a multistep progression from Barrett's esophagus to fully developed carcinoma, accelerated proliferation may indicate or precede genomic instability and, therefore, may be an important factor in the pathogenesis and/or prediction of malignant transformation. Ki-67 is a nuclear antigen expressed in proliferating cells, (G1, S, G2, and M phases) but not in resting cells (G0 phase). This study was undertaken to determine if Ki-67 expression correlates with the degree of dysplasia and if Ki-67 expression can help to differentiate those patients with or without dysplasia.
METHODS: The Ki-67 proliferation fraction in 87 paraffin embedded esophageal biopsies from 43 patients with the Ki-67 antibody (MIB-1) was analyzed using immunohistochemistry. Using a computerized proliferation index program (QNA v2.54, Becton Dickinson Cellular Imaging Systems, Inc., Elmhurst, IL), a Ki-67 score was derived for the luminal surface, upper esophageal crypt, lower crypt, and underlying glandular zone of the columnar-lined esophagus.
RESULTS: Significant differences in Ki-67 scores were noted in each zone among different histologic categories: normal gastric ([NG] n = 17); Barrett's without dysplasia ([ND] n = 17); low grade dysplasia ([LG] n = 21); high grade dysplasia ([HG] n = 14); and adenocarcinoma ([CA] n = 5). The pattern of Ki-67 expression was associated strongly with each histologic category. The percentage of Ki-67 positive nuclei in each mucosal zone statistically separated high grade from low grade dysplasia (P < 0.001). In high grade dysplastic tissues, the Ki-67 positive nuclei were found predominantly on the surface epithelium and upper crypt zones, whereas in low grade dysplasia, the majority of Ki-67 positive nuclei were found in the lower crypt zone. The number of Ki-67 positive nuclei in each mucosal component also was significantly different in Barrett's esophagus without dysplasia when compared with Barrett's esophagus with low grade dysplastic tissues. (P < 0.001) Staining patterns of indefinite for dysplasia by H & E staining separated into several distinct patterns (five LG, seven ND, one NG) whereas six biopsies with low grade dysplasia had a Ki-67 expression pattern more consistent with that of high grade dysplasia.
CONCLUSION: The Ki-67 staining pattern correlated with histologic findings in Barrett's esophagus and may represent an additional parameter for differentiating patients with or without dysplasia.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7812911     DOI: 10.1002/1097-0142(19950115)75:2<423::aid-cncr2820750202>3.0.co;2-5

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  37 in total

Review 1.  Molecular biology of Barrett's adenocarcinoma.

Authors:  B P Wijnhoven; H W Tilanus; W N Dinjens
Journal:  Ann Surg       Date:  2001-03       Impact factor: 12.969

2.  Time gated fluorescence spectroscopy in Barrett's oesophagus.

Authors:  M-A E J Ortner; B Ebert; E Hein; K Zumbusch; D Nolte; U Sukowski; J Weber-Eibel; B Fleige; M Dietel; M Stolte; G Oberhuber; R Porschen; B Klump; H Hörtnagl; H Lochs; H Rinneberg
Journal:  Gut       Date:  2003-01       Impact factor: 23.059

Review 3.  Early events during neoplastic progression in Barrett's esophagus.

Authors:  Brian J Reid
Journal:  Cancer Biomark       Date:  2010       Impact factor: 4.388

Review 4.  [Barrett's esophagus. An update].

Authors:  G B Baretton; D E Aust
Journal:  Pathologe       Date:  2012-02       Impact factor: 1.011

5.  Deletion at fragile sites is a common and early event in Barrett's esophagus.

Authors:  Lisa A Lai; Rumen Kostadinov; Michael T Barrett; Daniel A Peiffer; Dimitry Pokholok; Robert Odze; Carissa A Sanchez; Carlo C Maley; Brian J Reid; Kevin L Gunderson; Peter S Rabinovitch
Journal:  Mol Cancer Res       Date:  2010-07-20       Impact factor: 5.852

6.  Cell cycle phase abnormalities do not account for disordered proliferation in Barrett's carcinogenesis.

Authors:  Pierre Lao-Sirieix; Rebecca Brais; Laurence Lovat; Nicholas Coleman; Rebecca C Fitzgerald
Journal:  Neoplasia       Date:  2004 Nov-Dec       Impact factor: 5.715

7.  Defining Cancer Risk in Barrett's Esophagus: A Pathologist's Perspective.

Authors:  Amy E Noffsinger
Journal:  Gastrointest Cancer Res       Date:  2008-11

8.  Expression of Gastric Markers Is Associated with Malignant Potential of Nonampullary Duodenal Adenocarcinoma.

Authors:  Chihiro Minatsuki; Nobutake Yamamichi; Ken-Ichi Inada; Yu Takahashi; Kouhei Sakurai; Takeshi Shimamoto; Yosuke Tsuji; Kazuya Shiogama; Shinya Kodashima; Yoshiki Sakaguchi; Keiko Niimi; Satoshi Ono; Toru Niwa; Ken Ohata; Nobuyuki Matsuhashi; Masao Ichinose; Mitsuhiro Fujishiro; Yutaka Tsutsumi; Kazuhiko Koike
Journal:  Dig Dis Sci       Date:  2018-06-28       Impact factor: 3.199

Review 9.  History, molecular mechanisms, and endoscopic treatment of Barrett's esophagus.

Authors:  Stuart Jon Spechler; Rebecca C Fitzgerald; Ganapathy A Prasad; Kenneth K Wang
Journal:  Gastroenterology       Date:  2010-01-18       Impact factor: 22.682

10.  p53, Ki67 and cyclin D1 as prognosticators of lymph node metastases in laryngeal carcinoma.

Authors:  D Mielcarek-Kuchta; J Olofsson; W Golusinski
Journal:  Eur Arch Otorhinolaryngol       Date:  2003-10-09       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.